Mind Medicine (MindMed) Inc. (MNMD)

Market Cap	583.75M
Revenue (ttm)	n/a
Net Income (ttm)	-125.32M
Shares Out	70.50M
EPS (ttm)	-2.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	856,591
Open	8.67
Previous Close	8.65
Day's Range	8.22 - 8.78
52-Week Range	2.41 - 12.22
Beta	2.48
Analysts	Strong Buy
Price Target	23.00 (+179.81%)
Earnings Date	May 8, 2024

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: MNMD

Analyst Forecast

According to 7 analysts, the average rating for MNMD stock is "Strong Buy." The 12-month stock price forecast is $23.0, which is an increase of 179.81% from the latest price.

Price Target

$23.0

(179.81% upside)

Analyst Consensus: Strong Buy